Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $102.2 million.

  • Krystal Biotech's Total Liabilities rose 595.61% to $102.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.2 million, marking a year-over-year increase of 595.61%. This contributed to the annual value of $109.5 million for FY2024, which is 17561.57% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Total Liabilities is $102.2 million, which was up 595.61% from $97.7 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Total Liabilities ranged from a high of $109.5 million in Q4 2024 and a low of $12.4 million during Q1 2021
  • For the 5-year period, Krystal Biotech's Total Liabilities averaged around $56.4 million, with its median value being $42.3 million (2023).
  • As far as peak fluctuations go, Krystal Biotech's Total Liabilities surged by 45248.26% in 2022, and later plummeted by 3811.33% in 2023.
  • Quarter analysis of 5 years shows Krystal Biotech's Total Liabilities stood at $32.7 million in 2021, then rose by 10.7% to $36.2 million in 2022, then rose by 9.65% to $39.7 million in 2023, then soared by 175.62% to $109.5 million in 2024, then decreased by 6.61% to $102.2 million in 2025.
  • Its Total Liabilities stands at $102.2 million for Q3 2025, versus $97.7 million for Q2 2025 and $89.7 million for Q1 2025.